血液透析患者におけるスピロノラクトンの心血管疾患および脳血管疾患の罹患率と死亡率への影響

基本情報

NCT ID

NCT01687699

ステータス

完了

試験のフェーズ

第4相

試験タイプ

介入

目標被験者数

157

治験依頼者名

Dialysis Outcomes Heart Failure Aldactone Study Group

概要

Aldosterone receptor blockers reduce cardiac-related morbidity and mortality. Recently, we demonstrated that long-term low-dose spironolactone is clinically safe in many hemodialysis (HD) patients. In the present study, we assess whether low-dose spironolactone treatment reduces the high incidence of cardio- and cerebrovascular (CCV) morbidity and mortality in HD patients. The investigators' hypothesis is that aldosterone receptor blockade by spironolactone reduces the risk of both CCV morbidity and death among HD patients.

対象疾患

介入

依頼者（Sponsor）

実施施設 (1)